Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v4-FR | Version v1-EN | |
---|---|---|
Language | French | English |
Date Updated | 2022-06-01 | 2022-06-01 |
Drug Identification Number | 02248361 | 02248361 |
Brand name | VIVAXIM | VIVAXIM |
Common or Proper name | Combined Purified Vi Polysaccharide Typhoid and Inactivated Hepatitis A Vaccine | Combined Purified Vi Polysaccharide Typhoid and Inactivated Hepatitis A Vaccine |
Company Name | SANOFI PASTEUR LIMITED | SANOFI PASTEUR LIMITED |
Ingredients | HEPATITIS A VACCINE, INACTIVATED SALMONELLA TYPHI VI CAPSULAR POLYSACCHARIDE VACCINE | HEPATITIS A VACCINE, INACTIVATED SALMONELLA TYPHI VI CAPSULAR POLYSACCHARIDE VACCINE |
Strength(s) | 160UNIT 25MCG | 160UNIT 25MCG |
Dosage form(s) | SUSPENSION SOLUTION SUSPENSION SOLUTION | SUSPENSION SOLUTION SUSPENSION SOLUTION |
Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
Packaging size | 1 x 1.0 mL (single dose) dual chamber syringe | 1 x 1.0 mL (single dose) dual chamber syringe |
ATC code | J07CA | J07CA |
ATC description | BACTERIAL AND VIRAL VACCINES, COMBINED | BACTERIAL AND VIRAL VACCINES, COMBINED |
Reason for discontinuation | Business reasons | Business reasons |
Anticipated discontinuation date | ||
Actual discontinuation date | 2022-05-31 | 2022-05-31 |
Remaining supply date | 2022-05-31 | 2022-05-31 |
Discontinuation status | Discontinued | Discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | Discontinuation of the manufacturing of this product. | |
Health Canada comments |